Nutriband Inc.
NTRB•NASDAQ•Healthcare•Biotechnology

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOGareth Sheridan
Founded2016
Employees13
CountryUnited States
Fiscal YearFebruary - January

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.nutriband.com
Phone407 377 6695
Address
121 South Orange Avenue, Suite 1500 Orlando, Florida 32801 United States

Corporate Identifiers

CIK0001676047
CUSIP67092M208
ISINUS67092M2089
EIN81-1118176
SIC3842

Leadership Team & Key Executives

Gareth Sheridan
Founder, Chief Executive Officer and Director
Serguei Melnik
Founder, President, Company Secretary and Executive Chairman
Gerald Goodman
Chief Financial Officer and Chief Accounting Officer
Dr. Alan Smith Ph.D.
Chief Operating Officer and President of 4P Therapeutics
Dr. Jeffrey Patrick Pharm.D.
Chief Scientific Officer
Michael Myer
President of Pocono Pharmaceutical
Tyler Overk
Head of Active Intelligence